Improving how factor VIII treatment works in children with hemophilia A
Part of Blood & lymphatic, Genetic & congenital clinical trials.
This study looks at why the body sometimes stops responding to factor VIII treatment in hemophilia A. It aims to find patterns that help doctors predict and manage this, so they can keep the treatment working well.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have hemophilia A, which can be mild, moderate, or severe.
- You are under 18 years old.
- You are currently using a preventive treatment called NFT (a type of clotting factor replacement).
- You do not have acquired hemophilia A (a different condition that starts later in life).
- You do not have any other bleeding disorder.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new preventive treatment (NXT007) to help stop bleeding episodes in infants and children with hemophilia A. It aims to see if this treatment reduces the number of bleeds and improves quality of life.
This study tests a new medicine called NXT007 for people with hemophilia A. It compares NXT007 to standard factor VIII treatment to see if it works better at preventing bleeding episodes.
This study is looking at the safety and effectiveness of a factor VIII medicine called octocog alfa (used to treat bleeding) in men with severe hemophilia A in India. It will track how well the medicine works and any side effects during routine care.
This trial tests a new gene therapy called SPK-8011QQ for adults with severe or moderately severe hemophilia A. The goal is to see if a single infusion can help your body produce its own factor VIII, reducing or stopping the need for regular factor VIII injections.
This study checks joint health and bleeding risk in people with severe hemophilia A who are taking newer factor VIII treatments or emicizumab. It uses ultrasound and blood tests to see how well these therapies protect joints.
This study compares two ways to prevent bleeding in people with Hemophilia A while they play sports. It looks at whether factor VIII or emicizumab prophylaxis helps reduce bleeding during higher-risk sports activities.
Hear when a new Hemophilia A trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.